Lilly retatrutide more than doubles Ozempic weight loss in Phase 3 diabetes trial

Novo Nordisk's Ozempic is a brand of semaglutide approved by the FDA for type 2 diabetes, while Eli Lilly's Mounjaro is approved for the same disease. Lilly's Zepbound and Novo's Wegovy are approved for overweight and obesity. The companies have been running more head-to-head trials as they fight neck-and-neck for the obesity and diabetes markets, and such studies remain a bold bet, BioSpace reported.

Retatrutide, Lilly's investigational candidate, is designed to change that. It is a once-weekly injection that activates three hormone receptors: GLP-1, GIP and glucagon. Ozempic and Wegovy mimic GLP-1 alone, according to the National Institutes of Health, while Mounjaro and Zepbound mimic GLP-1 and GIP. The third target, glucagon, promotes fat burning even at rest. That combination has earned retatrutide the nickname triple-G and underpins Lilly's case for larger reductions in blood sugar and body weight than earlier incretin therapies.

The clinical program behind that case is TRANSCEND-T2D, which began in 2024 and has enrolled more than 2,050 participants across three registrational trials. TRANSCEND-T2D-2 is the head-to-head study at the center of the latest disclosure. It randomized 1,298 adults with type 2 diabetes inadequately controlled with metformin, with or without an SGLT2 inhibitor, in a 2:2:1 ratio to retatrutide 9 mg, retatrutide 12 mg or Ozempic 2 mg. Participants had a baseline A1C between 7.0% and 10.5% and were treated for 80 weeks. The main goal was to show retatrutide was at least as good as Ozempic on A1C; weight loss was a key secondary goal.

On October 28, 2026, Lilly disclosed topline results it described as positive across the primary and all key secondary endpoints. The company said retatrutide produced greater A1C reduction and substantially more weight loss than Ozempic's highest approved dose. It was the sixth clinical win for retatrutide in the Phase 3 program, according to BioSpace, and the first head-to-head comparison with another incretin in a late-stage trial.

Key Facts

Reuters reported on October 28, 2026 that both doses of retatrutide lowered A1C, a measure of average blood sugar over time, by 2.2 percentage points on average, compared with 1.8 points for Ozempic 2 mg at 80 weeks. The average baseline A1C was 8.3%. Lilly said it used Ozempic 2 mg as the comparator because that is the highest approved dose.

PR Newswire reported on October 28, 2026 that participants on retatrutide 9 mg lost an average of 44.3 pounds, or 19.5% of body weight, while those on 12 mg lost 47.4 pounds, or 20.9%. Participants on Ozempic 2 mg lost 20.9 pounds, or 9.4%. The average starting weight was 102.4 kilograms, or 225.8 pounds, with an average body mass index of 36.8. In absolute terms, the retatrutide arms lost roughly 20.1 kilograms and 21.5 kilograms, compared with about 9.5 kilograms for Ozempic.

Lilly said retatrutide also improved certain cardiovascular risk factors more than Ozempic, including non-HDL cholesterol, triglycerides and systolic blood pressure. Those are secondary findings. Detailed results will be presented at a future medical meeting and published in a peer-reviewed journal.

The safety profile was broadly similar to other incretin drugs, but not identical in frequency. The most common adverse events for retatrutide 9 mg, retatrutide 12 mg and Ozempic, respectively, were diarrhea at 28.3%, 32.7% and 26.4%; nausea at 21.2%, 23.8% and 21.3%; constipation at 14.2%, 13.1% and 19.8%; vomiting at 10.2%, 15.0% and 13.2%; and dyspepsia at 10.4%, 8.5% and 11.6%. Dysesthesia, a prickling or burning sensation, occurred in 4.8%, 6.5% and 2.7%. Urinary tract infections occurred in 5.8%, 4.2% and 5.8%.

Most events were mild to moderate, Lilly said. Discontinuation because of adverse events was 4.8% in the 9 mg arm and 7.9% in the 12 mg arm, compared with 2.7% for Ozempic. The company was direct about regulatory status: retatrutide is an investigational molecule that has not been approved by the FDA or any regulatory organization anywhere in the world, and anyone purporting to sell it to consumers is breaking the law. BioSpace reported on October 28, 2026 that Lilly has filed six lawsuits over illicit sales.

Analysis

The headline numbers are striking, but the most important detail is the design. Head-to-head studies are a bold bet, typically reserved for approved medicines seeking to show superiority over a rival, BioSpace noted. By testing retatrutide against the highest approved dose of Ozempic rather than a placebo, Lilly is trying to answer the question physicians, payers and patients ask: how does this drug compare with the standard of care? Even so, topline results are not a peer-reviewed publication, and the full safety and subgroup data still need scrutiny.

What this really means is that Lilly now has a credible claim to a new efficacy tier in type 2 diabetes, not just another me-too incretin. A 2.2-point A1C reduction is meaningful for patients whose baseline is 8.3%, and a roughly 20% body weight reduction is more than double the 9.4% seen with Ozempic in this trial. The cardiovascular risk factor improvements add to the commercial case. But the data do not prove that retatrutide is better for every patient. The higher discontinuation rate at 12 mg, the dysesthesia signal and the gastrointestinal side effects will shape real-world use, especially where tolerability and access determine how long patients stay on therapy.

The bigger picture here is that the obesity and diabetes market is moving from a two-horse race into a contest over multiple mechanisms. Lilly's triple agonist is aimed at patients who need more than GLP-1 alone, while Novo Nordisk is developing CagriSema, which it expects to win FDA approval for by the end of the year, according to ABC News. Neither drug is approved yet. The willingness to run head-to-head trials raises the bar for evidence and could complicate pricing and reimbursement negotiations.

There is also a commercial and legal dimension. BioSpace reported on October 28, 2026 that Lilly has a roughly $1 trillion market capitalization, a scale that gives it room to fund large trials and manufacturing. The black market for retatrutide, despite its unapproved status, shows how intense patient demand has become and how quickly an investigational molecule can be diverted into illicit supply. Lilly's six lawsuits may protect patients and the brand, but they are not a substitute for regulatory approval and physician oversight.

Why It Matters

For patients with type 2 diabetes and obesity, the trial offers a concrete comparison. The retatrutide arms lost 19.5% and 20.9% of body weight, against 9.4% for Ozempic, while A1C fell by 2.2 points on both retatrutide doses versus 1.8 points for Ozempic. Those differences are large enough to matter for participants who entered the study with an average body mass index of 36.8 and a baseline A1C of 8.3%. If approved, the drug would give patients and clinicians another option, though the full risk-benefit picture will depend on longer-term data and on how it performs outside a controlled trial.

For clinicians, the result reinforces the value of mechanism. Ozempic and Wegovy mimic GLP-1; Mounjaro and Zepbound add GIP; retatrutide adds glucagon. Retatrutide's third target is the key scientific difference from Ozempic, and the trial's weight loss gap suggests it adds effect, but the trade-off is a more complex safety profile. ABC News reported on October 28, 2026 that retatrutide also showed better heart benefits, including for cholesterol and blood pressure, and that any version consumers have seen online is from the black market and should not be consumed, according to the FDA. That warning is essential because retatrutide has no regulatory approval anywhere in the world.

For the companies, the readout strengthens Lilly's position ahead of a planned FDA submission and increases pressure on Novo Nordisk to respond with its own next-generation data. The market is no longer just about who has the best single GLP-1 drug. It is about who can demonstrate superior outcomes in direct comparisons, who can manufacture at scale and who can convince payers that a higher price is justified by larger clinical benefits. The TRANSCEND-T2D-2 result is a strong talking point on all three fronts, but it does not settle the competition.

Next Up

Lilly said it expects to submit retatrutide for FDA approval in the first quarter of 2027. Detailed TRANSCEND-T2D-2 results will be presented at a future medical meeting and published in a peer-reviewed journal. About 650 participants are continuing to receive retatrutide in an extension period for 24 more weeks. The TRANSCEND-T2D program has now enrolled more than 2,050 participants across three registrational trials.

Novo Nordisk's CagriSema is expected to win FDA approval by the end of the year, according to ABC News, setting up a broader contest over the next generation of incretin therapies. Neither drug is approved yet, and the FDA has warned that online versions of retatrutide are black market products. The coming months will be defined by regulatory review, peer review and the head-to-head evidence Lilly has just put on the table.